Dashboard Explore tenders Markets Buyers Competitors Pipeline Sign in

Loading…

Source data: TED (Tenders Electronic Daily, © European Union) and TenderNed, reused under EU open-data / TED reuse terms. TenderRadar is an independent service — not official, not endorsed by the issuing authorities.

Public beta · Data & sources · API · Corrections & takedown

Biosimilars: Infliximab IV, Tocilizumab IV en SC, Denosumab SC en Epoëtine alfa — TenderRadar

← Back to explorer

Biosimilars: Infliximab IV, Tocilizumab IV en SC, Denosumab SC en Epoëtine alfa

TED · 763149-2026Contract noticeCloses in 28 days · 2026-12-01

Buyer

NameIMELDA VZW

CountryBE

Published2026-11-03

Deadline2026-12-01

Value

Estimated—

Awarded—

CPV codes

33690000 Medical equipment & pharmaceuticals

Description

Biosimilars: Infliximab IV, Tocilizumab IV en SC, Denosumab SC en Epoëtine alfa

Source

View the official notice on TED ↗

Related parliamentary activity (suggestie)

Tweede Kamer documents (motions, questions, letters) that read as related to this — a semantic suggestion from motiefeed.nl, not an official link.

Beslisnota bij Kamerbrief over Stand van zaken toezeggingen eerstelijns apotheekzorg en geneesmiddelen · Bijlage · 2026-07-17 · 87%
Advies Inzet clesrovimab binnen het immunisatieprogramma tegen RSV · Bijlage · 2026-06-23 · 87%
Infectieziektenbestrijding · Brief regering · 2026-06-23 · 87%

Related parliamentary activity (suggestie)

Tweede Kamer documents (motions, questions, letters) that read as related to this — a semantic suggestion from motiefeed.nl, not an official link.

Beslisnota bij Kamerbrief over Stand van zaken toezeggingen eerstelijns apotheekzorg en geneesmiddelen · Bijlage · 2026-07-17 · 87%
Advies Inzet clesrovimab binnen het immunisatieprogramma tegen RSV · Bijlage · 2026-06-23 · 87%
Infectieziektenbestrijding · Brief regering · 2026-06-23 · 87%

Records451,468 tendersNewest notice2026-11-04Last ingest2026-11-04 · TED daily 06:00Parser health (7d)all runs clean